Neomorph, Inc., a biotechnology company pioneering molecular glue degraders to address previously undruggable proteins, today announced the closing of a $100 million Series B financing. The round was ...
Presentation in the New Drugs on the Horizon session to feature the development of NEO-811, a novel ARNT (HIF-1β)-targeted therapy in clear cell ...
4don MSN
Its new cancer drug makes cells self-destruct. Investors bet another $100M on this San Diego startup
San Diego startup Neomorph on Monday announced a new $100 million investment for its molecular glue that tricks cancer cells into self-destructing. Even as it awaits results from its first clinical ...
Novo intends to “fully integrate” AI capabilities across its operations. Elsewhere, Regeneron made its first foray into ...
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple ...
Saqib Islam, chief executive Officer of newly launched Beeline Medicines. The pace of private financing in biopharma steps up ...
AbbVie has completed the acquisition of Nimble Therapeutics. Credit: © AbbVie Inc. All rights reserved. · Pharmaceutical Technology · © AbbVie Inc. All rights ...
Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...
SAN DIEGO--(BUSINESS WIRE)--Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results